Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 9/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | PRKX | P51817 | 1/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.37 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13085997 | 0.86 | NPC1 (0.48) | HPGDNPC1RAB9ASMN1; SMN2JAK2 | |
| SCHEMBL2930992 | 0.85 | NPC1 (0.42) | HPGDNPC1RAB9ASMN1; SMN2JAK2 | |
| SCHEMBL2928969 | 0.84 | HPGD (0.44) | HPGDNPC1RAB9ASMN1; SMN2JAK2 | |
| SCHEMBL2925708 | 0.83 | RAF1 (0.47) | HPGDRAB9ARAF1BRAFPTGES | |
| SCHEMBL13086227 | 0.82 | HPGD (0.51) | HPGDNPC1RAB9ASMN1; SMN2JAK2 | |
| SCHEMBL13085993 | 0.81 | HPGD (0.46) | HPGDNPC1RAB9ASMN1; SMN2JAK2 | |
| SCHEMBL13086048 | 0.80 | HPGD (0.43) | HPGDNPC1RAB9ASMN1; SMN2JAK2 | |
| SCHEMBL13086212 | 0.79 | HPGD (0.45) | HPGDNPC1RAB9ASMN1; SMN2JAK2 | |
| SCHEMBL13085979 | 0.78 | TRPV1 (0.44) | HPGDNPC1RAB9ASMN1; SMN2RAF1 | |
| SCHEMBL2924892 | 0.78 | PTGES (0.45) | HPGDNPC1RAB9ASMN1; SMN2RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | AURKC, AURKA, AURKB | HPGD 3750/4885NPC1 653/4885RAB9A 3858/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | HPGD 3750/4885NPC1 653/4885RAB9A 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.